InflaRx N.V. (IFRX) Dividend History

InflaRx N.V. is a biopharmaceutical company focused on developing and commercializing therapies that target inflammatory diseases. The company's pipeline mainly includes monoclonal antibodies designed to inhibit the complement system's role in inflammatory processes, aiming to treat conditions such as hidradenitis suppurativa and other severe inflammatory disorders. Headquartered in the Netherlands, InflaRx leverages its expertise in immunology to develop innovative treatments for unmet medical needs.

Dividend History

InflaRx N.V. currently does not pay dividends

Company News

  • InflaRx announced that the Independent Data Monitoring Committee recommended stopping the Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility. The company will focus on its oral inhibitor INF904 and consider cost-saving measures.

    GlobeNewswire Inc.
  • InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: NRIX
  • Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to $0.6050 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Inspire Veterinary Partners, Inc. (NASDAQ: IVP) gained 99.9% to $0.3817 in pre-market trading after jumping over 22% on Thursday. Jaguar Health, Inc. (NASDAQ: JAGX) gained 29.1% to $0.1485 in pre-market trading after gaining around 12% on Thursday. TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares jumped 27.2% to $2.22 in pre-market trading following a 15% decline on Thursday. RiskOn International, Inc. (NASDAQ: ROI) gained 21.8% to $0.1481 in pre-market trading after gaining over 9% on Thursday. Vision Marine Technologies Inc. (NASDAQ: VMAR) shares climbed 19.7% to $0.9530 in pre-market trading. Cyngn Inc. (NASDAQ: CYN) surged 16.3% to $0.25 in pre-market trading. Cyngn shares jumped over 17% on Thursday after the ...

    Benzinga
  • The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

    The Motley Fool
  • Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: REVB
Page data last updated 07/23/2025 21:29:16 UTC